The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using a Compounding Pharmacy
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Tyler Morning Telegraph8h
Medicaid Now Covers GLP-1s for Obesity in Texas
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Hastings Tribune8h
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
The Mountaineer8h
North Carolina Medicaid Spend on GLP-1s for Obesity up 111% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Health risks from wildfire smoke linger 3 years after Marshall Fire
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
24/7 Wall St11h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...
The Motley Fool15h
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Over the course of 72 weeks, Lilly tested Zepbound and Wegovy on a population of adults with ... Adam Spatacco has positions ...
McKnight's Long-Term Care News17h
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).